AIIMS inks MoUs with public sector units for health infrastructure expansion

Jan 17, 2017 0

New Delhi– The All India Institute of Medical Sciences (AIIMS) on Tuesday inked Memorandums of Understanding (MoU) amounting to Rs 7,670 crore with public sector units to expand health infrastructure and facilities in the country.

According to the Health Ministry, the MoUs include a Rs 4,441 crore deal with NBCC (India) Limited, a Rs 2,500 crore agreement with HSCC (India) Limited and a Rs 729 crore accord with HITES HLL Life Care Ltd.

The agreement with NBCC for redevelopment envisages construction of 3,060 residential apartments at Ayur Vigyan Nagar campus and 868 apartments at West Ansari Nagar campus.

“The total augmentation of 3,928 units would take the total available residential units of AIIMS to 4,505,” said a statement from the Ministry.

The agreement with HLL Infra Tech Services Limited (HITES) is for procurement of all types of medical equipment and services, including Medical Gas Distribution System, for Central Sterile Services Department (CSSD) and Modular Operation Theatres for National Cancer Institute at AIIMS, Jhajjar in Haryana.

“Similarly, HSCC has been selected as a project management consultant for the design, tendering, supervision of engineering components and for equipment procurement and allied infrastructure works for the proposed National Cardiovascular Institute (NCVI) at the AIIMS second campus at Jhajjar,” the statement said.

The signing ceremony was presided over by Health Minister J.P. Nadda and Urban Development Minister M. Venkaiah Naidu.

Calling the signing of the MoUs as one of the most historic days for AIIMS, Nadda said: “The past two years have witnessed a historic growth in the form of infrastructure and other facilities.”

Nadda, on the occasion, assured that the government is committed to ensuring that the new AIIMS will meet the same standards of service as AIIMS, New Delhi.

“No effort will be spared to make them the very best,” he added.

Naidu said: “The profession of a doctor is very noble task and AIIMS has contributed significantly in providing quality healthcare. The expansion plans would not only improve medical education but will also provide greater access to world-class facilities to the citizens.”

Read More

India, Canada to partner in healthcare

Dec 12, 2016 0

Toronto–Canada, a global leader in universal healthcare, is partnering with India to help deliver quality and more accessible healthcare for the Indian masses.

Promoting quality healthcare in India will be one of the themes of the first-ever Canada-India Healthcare Summit, to be held in New Delhi early next year.

The summit will also discuss how Canada can bring down its own ballooning costs of universal healthcare by using India’s trained medical manpower, expertise in information technology and alternative medicines and its successful generic drugs research and development and manufacturing industry.

Making an announcement in this regard here, well known Indo-Canadian scientist Dr Lucky Lakshmanan, who will chair the summit, said: “Canada and India can leverage the strengths of each other in healthcare for mutual benefits.”

“Canada’s strength lies in providing quality healthcare from coast to coast. India’s strength is the ability to deliver healthcare at low cost, but its resources and expertise limit the accessibility of quality healthcare for people.”

Since Canada has the expertise in providing quality medicare from coast to coast, the summit will discuss how Canada can help in providing quality healthcare across India, he said.

The summit will also discuss how Indian expertise in IT can help Canada bring down the cost of its universal healthcare since it lacks trained doctor and nurse manpower.

“By using Indian IT expertise, Canadian doctors and nurses in big cities like Toronto can guide healthcare staff in far-off areas in delivering quality healthcare to people,” said Dr Lakshmanan.

Canada can also benefit from India in providing old-age care to its fast aging population, he said.

“With its huge pool of nurses, India also has an opportunity to provide old-age care for Canadians as the population is aging fast and provincial governments in Canada are looking at public-private partnership options in old-age care because of the rising costs.”

Because Indians are genetically much more prone to diabetes and heart diseases, the summit will discuss how Canada’s pioneering work in these fields can be useful for medicare providers in India.

“The substantial number of people of Indian origin have triggered some important research in Canada on diabetes and heart disease. Pioneering work being done in these fields can be very useful for healthcare providers in India,” said Romesh Chotai, who is the biggest importer of Indian generic drugs into Canada.

He will co-chair the Delhi health summit, which will also look at how Canada can benefits from India’s traditional and alternative healthcare practices such as ayurveda and homoeopathy.

Many Canadian companies — from hospital infrastructure, medical devices, telemedicine and medical equipment sectors — are coming to the health summit to explore partnership possibilities with Indian companies.

The Canada-India Health Summit is an initiative of the Canada-India Foundation in collaboration with Ontario’s Ministry of International Trade. (IANS)

Read More

India urged to take better initiatives at stroke management

Dec 5, 2016 0

Gurugram– A global meet of experts on neuro sciences — which saw over 500 participants — on Monday called upon the Indian government to increase initiatives for more awareness on brain strokes.

According to them, the necessity for better awareness was more among women as in certain parts of the country women are five times more prone to stroke incidences than men.

“This is attributable to the poor socio-economic status and literacy rates among women. The average age of patients with stroke in developing countries (India) is 15 years younger than those in developed countries like US,” according to the findings of the doctors at the summit, which concluded on Monday.

“Stroke unit implementation remains a big challenge in India. At present in India, there are approximately 35 stroke units and they are predominantly in private sector hospitals in the cities,” said Vipul Gupta, Director, Neuro-intervention, at Artemis Hospital.

He addeed, “Many of the private hospitals lack CT scan facility and they refer for incentives to other hospitals or centres. This results in crucial time being lost. On the other hand, public hospitals lack a dedicated team and place to manage stroke patients. We will be launching a stroke app for patients and doctors.”

Experts from the US, Europe, Oman, Nepal and Bangladesh who participated in the summit showcased the advances in stroke management.

“Lack of awareness, lower rates of literacy and poor primary health care services are the key attributable factors in India behind rising strokes,” said Asai Blaise Baxter, US based neuro-intervention specialist. (IANS)

Read More

Central regulations for ayurvedic industry soon

Dec 4, 2016 0

Kolkata– The AYUSH Ministry is planning to draw up a central regulatory framework for ayurvedic industry, an official said on Sunday.

“Presently, the total enforcement is on the hands of state licensing authorities. We are going to have some regulatory framework in the centre so that many issues related to regulations, quality control can be taken up with state level authorities,” said Ministry’s Adviser (ayurved) D.C. Katoch.

“If a licence is to be taken for the first time, the proposal should come to centre. The central technical committee will review the proposal and accordingly, the license should be cleared,” he added.

D.C. Kastoch (Photo curtsy: MPR colloquium)

D.C. Kastoch (Photo courtesy: MPR colloquium)

The ministry is also mulling to take steps to stop false claims through advertisements, Katoch said on the sidelines of the AROGYA Expo and the seventh World Ayurvedic Congress here.

The ministry is looking to set up more clusters to facilitate small and medium enterprises in ayurvedic industry.

“The scheme for setting up clusters was started earlier. About 5-6 clusters across states are functional. The ministry has been considering proposals for setting up new clusters,” said Katoch.

The government supports 60 per cent of the project cost while the industry players need to take care of 40 per cent of the cost, he said.

The ministry has also taken initiatives to standardise terminology used in the ayurvedic practices.

“There are many books in the ayurveda literature and there are many terms being used for a particular practice. These practices are not interpreted uniformly by the stakeholders. The meaning of these terms has to be standardised to globalise the understanding of ayurveda,” said Katoch.

The ministry has entered into an agreement with World Healh Organisation (WHO) to develop some document for global positioning of ayurveda.

He further said that raw materials and medicinal plants are being sourced directly from the growers. The government has been planning to facilitate the setting up of mandis (marketplace) to strengthen buyers-growers interface.

“The ministry has been drawing up plans to facilitate the setting up mandis,” he added.

Read More

My Home Group to foray into pharma, bulk drugs

Nov 7, 2016 0

Hyderabad– My Home Group, a diversified business conglomerate, plans to foray into pharma and bulk drugs.

A top company official said on Monday that concrete plans for the new business will be announced in six months.

The Hyderabad-headquartered group, with presence in cement, construction, power and transport, currently has a total turnover of Rs 5,000 crore.

S. Sambasiva Rao, Executive Director, My Home Industries Private Limited (MHIPL), was talking to reporters after unveiling a new identity for its flagship cement brand — Maha Cement.

He also announced that the group’s turnover from cement will go up to Rs 5,000 crore in two to three years from the existing Rs 3,000 crore.

MHIPL, a My Home Group company, is a 50:50 joint venture with CRH Plc, Ireland, the world’s second largest building material company.

He said the new cement plant at Tuticorin in Tamil Nadu would commence production by January end 2017. The plant with a production capacity of 1.23 million tonnes is coming up with an investment of Rs 250 crore.

Rao said the new plant would help the company achieve the target of 10 million tonnes capacity.

The company also proposed to set up another cement plant with a capacity of 1.5 million tonnes in Guntur district of Andhra Pradesh.

Its existing plants are located in Nalgonda district in Telangana, Kurnool and Visakhapatnam districts in Andhra Pradesh.

A major cement player in south India, Maha Cement has expanded to Odisha, Bihar, West Bengal and Chhattisgarh. “We are looking at pan India presence,” he said. (IANS)

Read More

Telangana, Johnson & Johnson sign MoU to make state TB free

Oct 14, 2016 0

Hyderabad– The Telangana government has entered into an MoU with pharma, life sciences and healthcare multinational company Johnson & Johnson to work together for making the state tuberculosis free, it was announced here on Friday.

The New Jersey-based Johnson & Johnson will play an active role in the project by assisting the state government in achieving the goal.

The MoU was signed when Industries Minister K.T. Rama Rao called on top leadership of the company on the second day of his business visit to the US.

Rama Rao met Paul Stoffel, Chief Scientific Officer and Chairman of Pharmaceuticals Division, Melinda Richter, Head of JLabs and Jonathan Collard, VP, Government Affairs and Policy, Asia Pacific.

K.T. Rama Rao

K.T. Rama Rao

Stoffel was very enthusiastic about proposed Hyderabad Pharma City, and will be visiting India and Hyderabad next year, said a statement from the minister’s office here on Friday.

Richter assured the Telangana delegation that they would explore the possibility of setting up of JLabs unit in Hyderabad.

Later, the minister met Sanat Chattopadhyay, Executive VP and President, Merck Manufacturing Division, who mentioned the firm’s intent for a social partnership with Telangana Government on arresting infant diarrhoea.

Merck also expressed interest in setting up manufacturing base in Telangana in collaboration with local partners. It also evinced interest in setting up “vaccine centre of excellence” in Hyderabad which will also be used for imparting skills, providing training based on the specific requirement of the companies.

Nanette Cocero, President for Emerging Markets for Innovative Health business, Pfizer and Jeffery T. Hamilton, Senior Director, Pfizer, during their discussions with Minister explained about Pfizer’s ECHO project in the area of breast cancer screening.

The minister elaborated on the steps Telangana Government initiated to boost the pharma sector in Hyderabad and invited Pfizer to associate with Research and Innovation Circle of Hyderabad (RICH).

Another MoU was signed with IV2 Alliance, a non-profit corporation and one that works in tandem with US Food and Drug Administration (USFDA) to promote collaboration within the scientific, research and provider communities to achieve advances in the field of healthcare and wellness.

USFDA in a written communication stated that Pharma City near Hyderabad can be the first of the international clusters it seeks to bring together to link scientific and medical advances from across the globe for better healthcare.

Read More

India approves setting up of first medical devices technology park

Oct 5, 2016 0

New Delhi–Giving a “Make in India” a push in the field of medical technology, the Union Cabinet here on Wednesday approved “mini Ratna” public sector undertaking HLL Lifecare to sub-lease its land for setting up the country’s first medical devices manufacturing park, an official statement said.

“The Union Cabinet chaired by Prime Minister Narendra Modi has given its approval to HLL Lifecare to sub-lease 330.10 acres of land at Chengalpattu, located in the outskirts of Chennai, to set up a medical devices manufacturing park (Medipark) through a special purpose vehicle,” the statement said.

Indian Prime Minister Mody

Indian Prime Minister Mody

The shareholding of HLL in the project, which is expected, would be above 50 per cent, it added.

The Medipark project will be the first manufacturing cluster in the medical technology sector in the country, envisaged to boost the local manufacturing of hi-end products at a significantly lower cost, resulting in affordable healthcare delivery, particular in diagnostic services to a large section of people.

“Medipark will be developed in phases, spread over seven years for completion. In the first phase, physical infrastructure will be developed and plots will be leased from third year onwards. Knowledge management centre will be developed in the second phase,” it said.

“It would contribute to the development of medical devices and technology sector and allied disciplines in the country, which is still at a nascent stage besides generating employment and give a boost to the government’s ‘Make in India’ campaign,” it added.

HLL will sublease the land to investors, through a transparent bidding process to investors desirous to set up manufacturing units for medical equipment and devices.

Read More

Medical tourism in India needs quality investment

Oct 3, 2016 0

Greater Noida–India needs to focus on quality investment to remain globally competitive in the area of medical tourism, Union Health secretary C.K. Mishra said on Monday.

Mishra’s remarks came at the inaugural ceremony of the second edition of “Advantage Health Care India” (AHCI), an initiative of the Ministry of Commerce & Industry, in association with the Federation of Indian Chambers of Commerce & Industry (Ficci) and Service Export Promotion Council (SEPC).

C.K. Mishra

C.K. Mishra

Addressing the gathering of over 500 delegates from around the globe, Mishra said that Indian healthcare has been constantly improving and globally acknowledged.

“However, given the scenario, it is time for both celebration and introspection — celebration, as the sector has done well and is continuously striving to do well, and introspection, because there is still a lot to do, as there is a huge opportunity still to be tapped,” he observed.

On the occasion, the Secretary, along with other dignitaries, released the “Empanelment Criteria for Medical Facilitators”, prepared by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) under the guidance of Ministry of Commerce & Industry, supported by Ficci.

Ficci President Harshavardhan Neotia and Ficci Chairperson Sangita Reddy were also present at the event.

Read More

Indian company joins hands with Mass General Hospital for 3D post-processing services

Sep 17, 2016 0

Bengaluru–City-based tele-diagnostic delivery company Teleradiology Solutions (TRS) on Saturday announced a collaboration with Massachusetts General Hospital (MGH) in Boston – one of the top-ranked hospitals in the US — to offer 3D image post-processing services.

Three dimensional images are fast and easy to read and help physicians diagnose and treat a wide range of patients with confidence and clarity.

Arjun Kalyanpur

Arjun Kalyanpur

“There has been increasing deployment and utilisation of high-end CT and MRI scan equipment globally as well as in India, and such high resolution imaging requires effective 3D post-processing for its benefits to be most optimally realised,” Arjun Kalyanpur, Founder and CEO of Teleradiology Solutions, said in a statement.

“As an example, 3D image post-processing of aneurysms and vessel blockages that may potentially result in life threatening complications can greatly facilitate their diagnosis, treatment and subsequent follow-up of such conditions, thereby benefiting treating physicians and impacting patients,” Kalyanpur explained.

TRS has invested $300,000 in a 3D Imaging Lab facility in Bengaluru, which will be manned by a specialised team of 3D-trained radiologists.

As a result of the new collaboration, Massachusetts General Hospital will make available its proprietary 3D protocols to TRS, the statement said.

This collaboration is likely to open up new patient care opportunities in India as well as across Asia, Africa and other parts of the world as the technology and 3D post-processing services can be offered to other hospitals as well.

“We are pleased to have the opportunity to work closely with TRS to enhance the diagnostic capabilities and timeliness of information that can help improve lives for patients,” Gordon J Harris, Director, 3D Imaging Service, Massachusetts General Hospital said.

“We hope that access to this technology can expand to providers in South Asia, as high-quality post-processing 3D imaging could have a significant impact on care – particularly emergency and trauma care – across the region,” Harris noted. (IANS)

Read More

Dr Reddy’s to market Amgen’s three medicines in India

Sep 16, 2016 0

Hyderabad– Pharma major Dr. Reddy’s Laboratories has expanded its strategic collaboration with Amgen, one of the world’s leading independent biotechnology companies, to market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis.

Under this collaboration, according to a press statement from Dr. Reddy’s on Friday, the company will commercialise Amgen’s XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.

The collaboration leverages the capabilities of both companies, combining Amgen’s innovative therapies with Dr. Reddy’s deep understanding of patient and physician needs in India, the statement said.

“These medicines provide unique treatment options to physicians to address unmet medical needs in the area of oncology and osteoporosis,” said M.V. Ramana, the Executive Vice President & Head of Emerging markets and India Business, Dr Reddy’s.

“We are happy to strengthen our relationship with Dr Reddy’s. Amgen is committed to addressing unmet medical needs of patients in India, and we are pleased with the commitment Dr Reddy’s has demonstrated towards making our medicines available in India as quickly as possible,” said Penny Wan, the Amgen Vice President & General Manager, Japan Asia Pacific Region.

Last year, Dr. Reddy’s had announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen’s Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India. (IANS)

Read More